Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CTOR 
Citius Oncology, Inc. (CTOR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: CTOR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 121.35% | Avg. Invested days 51 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 149.49M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 2.93 | 52 Weeks Range 0.55 - 6.19 | Updated Date 10/17/2025 |
52 Weeks Range 0.55 - 6.19 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.48% | Return on Equity (TTM) -107.54% |
Valuation
Trailing PE - | Forward PE 35.59 | Enterprise Value 160805269 | Price to Sales(TTM) - |
Enterprise Value 160805269 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 83513442 | Shares Floating 10644293 |
Shares Outstanding 83513442 | Shares Floating 10644293 | ||
Percent Insiders 88.67 | Percent Institutions 0.71 |
Upturn AI SWOT
Citius Oncology, Inc.
Company Overview
History and Background
Citius Oncology, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing critical care products, with a focus on anti-cancer agents. Founded to address unmet medical needs in cancer care, the company is working towards commercialization of its leading asset.
Core Business Areas
- Mino-Lok: This is an antibiotic lock solution designed to salvage central venous catheters (CVCs) in patients with catheter-related bloodstream infections (CRBSIs).
- Halo-Lido: A late-stage novel formulation of halobetasol and lidocaine designed to alleviate hemorrhoids.
Leadership and Structure
The leadership team consists of experienced professionals in the pharmaceutical industry. The organizational structure includes departments for research and development, clinical trials, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Mino-Lok: Mino-Lok is Citius Oncology's lead product candidate. It aims to treat catheter-related bloodstream infections (CRBSIs). There is currently no market share data available for Mino-Lok as it is still undergoing regulatory approval and has not been commercialized. Competitors in treating CRBSIs include companies providing antibiotics, catheter removal services and other catheter maintenance products.
- Halo-Lido: Halo-Lido is a prescription product candidate for the relief of hemorrhoids and is in late stage trials with planned NDA submission in Q4 of 2024. There is currently no market share data available for Halo-Lido as it is still undergoing regulatory approval and has not been commercialized. Competitors for hemorrhoid relief products include companies offering prescription and over the counter treatments such as Abbvie with Proctofoam HC and Preparation H from Haleon
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for innovative therapies. The oncology market is experiencing growth due to an aging population and advancements in cancer diagnostics and treatment.
Positioning
Citius Oncology aims to position itself as a key player in the critical care and oncology spaces by developing and commercializing innovative therapies to address unmet medical needs.
Total Addressable Market (TAM)
The TAM for CRBSIs and hemorrhoids is substantial, representing a significant market opportunity for Citius Oncology. Specific TAM estimates are difficult to pinpoint without further clinical trial data and market analysis.
Upturn SWOT Analysis
Strengths
- Late-stage product pipeline
- Experienced management team
- Potential for addressing unmet medical needs
- Focus on critical care and oncology
Weaknesses
- Reliance on successful clinical trial outcomes
- Dependence on regulatory approvals
- Limited revenue generation prior to product commercialization
- Financial resources necessary to see clinical trials to the end.
Opportunities
- Expansion of product pipeline through strategic acquisitions or partnerships
- Potential for accelerated regulatory pathways (e.g., breakthrough therapy designation)
- Increasing demand for innovative therapies in oncology
- Geographic expansion into new markets
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Changes in healthcare regulations and reimbursement policies
Competitors and Market Share
Key Competitors
- BMRN
- JNJ
- PFE
Competitive Landscape
Citius Oncology faces competition from established pharmaceutical companies with greater resources and broader product portfolios. Citius' advantage relies on it's novel approaches and successfull clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been largely dependent on clinical trial progress and investor sentiment.
Future Projections: Future growth is dependent on successful commercialization of Mino-Lok and other pipeline assets. Analyst estimates vary depending on clinical trial outcomes.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Mino-Lok and Halo-Lido, and efforts to secure regulatory approvals.
Summary
Citius Oncology is a biopharmaceutical company with late-stage product candidates targeting unmet medical needs. The company's success hinges on positive clinical trial outcomes and regulatory approvals. Challenges include competition from larger pharmaceutical companies and the inherent risks associated with drug development. Successful commercialization of their products will drive the company's growth, but regulatory setbacks and financial constraints pose threats. Overall, Citius Oncology's growth is contingent on mitigating these risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Citius Oncology Investor Relations
- SEC Filings
- Company Press Releases
- Public Domain News Articles
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Investment decisions should be made in consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Citius Oncology, Inc.
Exchange NASDAQ | Headquaters Cranford, NJ, United States | ||
IPO Launch date 2022-12-08 | CEO, President & Executive Chairman Mr. Leonard L. Mazur | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees - | Website |
Full time employees - | Website | ||
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.